Neuroactive Steroid Therapy for Epilepsy With Lower Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmacotherapies for neurological disorders such as epilepsy have limited efficacy and are associated with severe toxicity, highlighting an unmet need for novel therapeutic compounds that can effectively treat epilepsy and its associated symptoms with improved tolerability.
Innovation Solution
Administration of 3α-hydroxy-3β-methoxymethyl-21-(1′-imidazolyl)-5α-pregnan-20-one (Compound 1) or its pharmaceutically acceptable salts, either alone or in combination with sodium channel blockers, to modulate γ-aminobutyric acid type A (GABAA) receptors and inhibit neuronal sodium current, thereby reducing seizure frequency and severity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard NaV-targeting AEDs (carbamazepine, oxcarbazepine, phenytoin) are used to block sodium channels and reduce neuronal excitability, then seizure control is improved, but severe toxicity occurs including ataxia, lethargy, vomiting, and seizures
Solution Approach 1:
The patent changes the chemical structure parameters of neuroactive steroids by introducing specific substituents (imidazolyl group at C21, methoxymethyl group at C3β) to modify the pharmacological profile. This structural modification allows Compound 1 to achieve effective GABAA receptor modulation at therapeutic doses while reducing off-target effects and toxicity associated with conventional AEDs
Solution Approach 2:
The patent combines multiple pharmacological mechanisms by using Compound 1, which acts as a positive allosteric modulator of GABAA receptors. This composite approach integrates enhanced GABAergic inhibition with favorable pharmacokinetic properties, creating a therapy that addresses both efficacy and tolerability requirements
2Reliability
If current pharmacotherapies are used to treat epilepsy, then some seizure control is achieved, but efficacy is substantially limited and tolerability is poor
Solution Approach 1:
The patent modifies key pharmacological parameters by developing Compound 1 with optimized potency and selectivity for GABAA receptors. The compound achieves effective seizure control at doses that minimize adverse effects, improving the therapeutic index compared to conventional AEDs
Solution Approach 2:
The patent uses neuroactive steroids as intermediary compounds that indirectly enhance GABAergic transmission through positive allosteric modulation of GABAA receptors. This indirect mechanism provides smoother pharmacological action with fewer abrupt side effects compared to direct channel blockers
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Compound 1 reduces seizures in patients with epilepsy, including various epilepsy syndromes and associated symptoms, with a mean steady state AUC0-24 of about 600 ng·h/mL to 900 ng·h/mL and Cmax of about 125 ng/ml to 250 ng/mL, providing a safer and more effective treatment option.
Implementation Method 1
Its primary molecular target is the γ-aminobutyric acid type A (GABAA) receptor, where it acts as a positive allosteric modulator (PAM) of channel function
Implementation Method 2
blockade, and consequent inhibition of neuronal sodium current (INa), is ideally positioned to reduce excitability
Data Source
AI summary
The disclosure relates to methods of treating a neurological disorder, such as epilepsy or an epilepsy syndrome, with Compound 1 or pharmaceutically acceptable salts thereof, alone, or in combination with sodium ion (Na+) channel blockers.